The use of psychotropic medications for chronic insomnia in clinical practice

Close metadata

Recommended articles:

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36

Melatonin for the regulation of sleep and other biological rhythms. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):8-13

The effectiveness of suggestive techniques to improve sleep is enhanced by combining with sound stimulus based on binaural beats. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):20-25

Effects of slow-wave sleep fragmentation and rapid eye movement sleep fragmentation on melatonin secretion. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):26-32

Management of patients with insomnia and polymorbidity. A draft of the clinical guidelines. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):39-52

Trait and state anxiety, symptoms of insomnia and their influence on daytime functioning in adolescent girls. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):66-71

Successful combinations of drug and non-drug therapy for low back pain. Russian Journal of Pain. 2024;(1):57-67

Effectiveness of Anvifen in the treatment of insomnia in elderly patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):91-96

Pathogenetic basis of modern approaches to the therapy of sleep disorders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74

Posttraumatic stress disorder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68

Chronic insomnia is a common sleep disorder. In its treatment, both non-drug and drug approaches are used. The therapeutic concept is based on a three-component model of sleep regulation. Psychotropic drugs of various pharmacological groups are used for the treatment of chronic insomnia. The peculiarities of the effect of these drugs in various clinical situations are discussed.

Keywords:

sleep

insomnia

hypnotics

pharmacotherapy

cognitive-behavior therapy of insomnia

Authors:

Poluektov M.G.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-6215-0918

Received:

06.04.2021

Accepted:

06.04.2021

List of references:

Somnologija i medicina sna. Nacional’noe rukovodstvo pamjati A.M. Vejna i Ja.I. Levina (2-e izd., dop. i pererab.). Pod red. Poluektova M.G.. M.: Medkongress; 2020. (In Russ.).
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gonçalves M, Hertenstein E, Jansson-Fröjmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Weeß HG, Wichniak A, Zavalko I, Arnardottir ES, Deleanu OC, Strazisar B, Zoetmulder M, Spiegelhalder K. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700. https://doi.org/10.1111/jsr.12594
Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res. 2016;5:918. https://doi.org/10.12688/f1000research.8729.3
Sweetman A, Putland S, Lack L, McEvoy RD, Adams R, Grunstein R, Stocks N, Kaambwa B, Van Ryswyk E, Gordon C, Vakulin A, Lovato N. The effect of cognitive behavioural therapy for insomnia on sedative-hypnotic use: A narrative review. Sleep Med Rev. 2021;56:101404. https://doi.org/10.1016/j.smrv.2020.101404
Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24(12):726-731. https://doi.org/10.1016/s0166-2236(00)02002-6
Stone BM, Turner C, Mills SL, Paty I, Patat A, Darwish M, Danjou P. Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. Br J Clin Pharmacol. 2002;53(2):196-202. https://doi.org/10.1046/j.-5251.2001.01520.x
Arroll B, Fernando A 3rd, Falloon K, Goodyear-Smith F, Samaranayake C, Warman G. Prevalence of causes of insomnia in primary care: a cross-sectional study. Br J Gen Pract. 2012;62(595):e99-103. https://doi.org/10.3399/bjgp12X625157
Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ 3rd, Rosenbaum JF, Fava M. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-225. https://doi.org/10.4088/jcp.v60n0403
Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, Inada K, Kikuchi T, Katsuki A, Kishida I, Sugawara Kikuchi Y, Yasui-Furukori N; Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020;266:626-632. https://doi.org/10.1016/j.jad.2020.01.149
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307-349. https://doi.org/10.5664/jcsm.6470
Wilson S, Anderson K, Baldwin D, Dijk DJ, Espie A, Espie C, Gringras P, Krystal A, Nutt D, Selsick H, Sharpley A. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol. 2019;33(8):923-947. https://doi.org/10.1177/0269881119855343
Scantlebury A, Mcdaid C, Dawson V, Elphick H, Fairhurst C, Hewitt C, Parker A, Spiers G, Thomas M, Wright K, Beresford B. Non-pharmacological interventions for non-respiratory sleep disturbance in children with neurodisabilities: a systematic review. Dev Med Child Neurol. 2018;60(11):1076-1092. https://doi.org/10.1111/dmcn.13972
Haimov I, Laudon M, Zisapel N, Souroujon M, Nof D, Shlitner A, Herer P, Tzischinsky O, Lavie P. Sleep disorders and melatonin rhythms in elderly people. BMJ. 1994;309(6948):167. https://doi.org/10.1136/bmj.309.6948.167
Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, Zisapel N. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27(1):87-98. https://doi.org/10.1185/03007995.2010.537317
Parrino L, Smerieri A, Giglia F, Milioli G, De Paolis F, Terzano MG. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clin Neuropharmacol. 2008;31(1):40-50. https://doi.org/10.1097/wnf.0b013e3180674e0e
Morin CM, Beaulieu-Bonneau S, Ivers H, Vallières A, Guay B, Savard J, Mérette C. Speed and trajectory of changes of insomnia symptoms during acute treatment with cognitive-behavioral therapy, singly and combined with medication. Sleep Med. 2014;15(6):701-707. https://doi.org/10.1016/j.sleep.2014.02.004
Beaulieu-Bonneau S, Ivers H, Guay B, Morin CM. Long-Term Maintenance of Therapeutic Gains Associated With Cognitive-Behavioral Therapy for Insomnia Delivered Alone or Combined With Zolpidem. Sleep. 2017;40(3):zsx002. https://doi.org/10.1093/sleep/zsx002
Morin CM, Bélanger L, LeBlanc M, Ivers H, Savard J, Espie CA, Mérette C, Baillargeon L, Grégoire JP. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med. 2009;169(5):447-453. https://doi.org/10.1001/archinternmed.2008.610

Close metadata